Results 131 to 140 of about 58,092 (289)
Chinese Guidelines for the Diagnosis and Surgical Treatment of Adult Obstructive Sleep Apnea (2024)
World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.ABSTRACT
Obstructive sleep apnea (OSA) is a common chronic disorder characterized by abnormal breathing during sleeping. OSA can damage various organs throughout the body and is burdensome, both socially and economically. Moreover, as OSA has been increasingly studied in recent years, new evidence‐based guidelines for its diagnosis and surgical ...Working Group of Guideline for the Diagnosis and Surgical Treatment of Adult OSA, Subspecialty Group of Laryngopharyngology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association, Subspecialty Group of Voice, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery +7 morewiley +1 more sourceDecreased Production of Tissue Plasminogen Activator in Endothelial Cells From Nasal Polyps
World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.ABSTRACT Introduction
Previous studies have demonstrated that chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by excessive fibrin deposition which is related to impaired production of tissue plasminogen activator(t‐PA) by epithelial cells.Qian‐Qian Zhang, Chen Zhang, Jia‐Ni Chen, Fu‐Ying Cheng, Yi‐Zhang Wang, Shi‐Rui Xue, Huan Wang, De‐Hui Wang, Xi‐Cai Sun, Li Hu +9 morewiley +1 more sourceThe Utility of Intranasal Corticosteroids in Association With Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: A Real‐Life Multicenter Study by a Tuscany Group
World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.ABSTRACT Objective
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition often associated with other type‐2 diseases. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has revolutionized the treatment of severe CRSwNP.Pietro Orlando, Giuseppe Licci, Marella Reale, Veronica Seccia, Alessia Giorli, Paolo Iannicelli, Dario Zaccari, Valentina Rossi, Jacopo Cambi, Stefano Berrettini, Marco Mandalà, Gianluca Leopardi, Antonio Sarno, Luca Muscatello, Simone Bocuzzi, Franco Trabalzini, Giandomenico Maggiore, Oreste Gallo +17 morewiley +1 more sourceInflammatory Shift in Chronic Rhinosinusitis Amidst Guangzhou's Urbanization (2000–2018)
World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.ABSTRACT Background
Chronic rhinosinusitis (CRS) exhibits temporal and geographic diversity in pathological endotypes with progressive eosinophilic infiltration, while the underlying causes remain unclear. Current pathological endotypes determination relies on mean cell count per high‐power field, requiring accuracy optimization.Ning Kang, Man‐Hou Chao, Xin Luo, Feng‐Wen Shan, Zi‐Xuan Hua, Ze‐Zhi Guo, Hua‐Mei Yan, He Zhang, Tong Wu, Min Zhou, Rui Zheng, Shuo Wu, Xue‐Kun Huang, Zhao‐Hui Shi, Ya‐Na Zhang, Ji Yang, Qin‐Tai Yang +16 morewiley +1 more sourceThai Translation and Validation of Chronic Rhinosinusitis‐Patient Reported Outcome (CRS‐PRO)
World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.ABSTRACT Objectives
The Chronic Rhinosinusitis Patient‐Reported Outcome (CRS‐PRO) questionnaire was recently developed for use in chronic rhinosinusitis (CRS) patients. This instrument was developed using current diagnostic criteria. This study aimed to translate and validate CRS‐PRO for Thai CRS patients.Wirach Chitsuthipakorn, Vorachai Pooldum, Juthaporn Phetpong, Saranath Lawpoolsri, Dichapong Kanjanawasee, Patlada Kowatanamongkon, Kittichai Mongkolkul, Kachorn Seresirikachorn, Kornkiat Snidvongs +8 morewiley +1 more source“Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps
Allergy, EarlyView.This study aimed to evaluate the feasibility of extending dupilumab dosing intervals in T2‐CRSwNP by assessing how many patients maintain disease control with once‐every‐12‐weeks (Q12W) dosing and comparing clinical characteristics of super‐responders and excellent responders. Tapering of dupilumab to Q12W appears feasible in super‐responding patients. P. E. Vonk, J. J. Otten, H. B. E. Elzinga, R. J. L. van der Lans, G. F. J. P. Adriaensen, L. B. L. Benoist, D. R. Hoven, W. J. Fokkens, S. Reitsma, PolyREG Consortium, A.B. Rinia, I. Krebbers, I.J. Kleiss, M. E. Cornet +13 morewiley +1 more sourceThe International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria
Allergy, EarlyView.ABSTRACT
This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and ...T. Zuberbier, Z. Abdul Hameed Ansari, A. H. Abdul Latiff, M. M. Abuzakouk, M. S. Agcaoili‐De Jesus, R. C. Agondi, M. Al‐Ahmad, A. A. Alangari, H. Alhameli, C. D. Alonso Bello, S. Alshareef, S. Al‐Tamemi, S. Altrichter, H. Al Wahshi, S. Aquilina, M. Araújo, R. Arnaout, R. Asero, B. Ballmer‐Weber, C. Bangert, A. Bauer, M. Ben‐Shoshan, J. A. Bernstein, C. Bindslev‐Jensen, M. Bizjak, I. Boccon‐Gibod, H. Bonnekoh, L. Bouillet, K. Brockow, Z. Brzoza, M. Bulatović Ćalasan, A. Bulkhi, T. Buttgereit, A. Bygum, T. Caballero, O. Calderon, R. Campos, M. Cancian, E. Carne, M. A. Castor, I. Cerecedo, T. Çetinarslan, I. Cherrez‐Ojeda, N. Chkhikvadze, H. J. Chong‐Neto, K. Choo, G. Christoff, C.‐Y. Chu, K. Ciupka, N. Conlon, C. Costa, T. Craig, P. Criado, I. Danilycheva, R. Darlenski, E. De Arruda Chaves, L. de Montjoye, M. S. Doutre, A. Du‐Thanh, D. Ebo, S. Elkhalifa, S. Elmariah, T. El‐Shanawany, L. F. Ensina, R. Ertaş, R. Fachini Jardim Criado, M. Ferrer, S. Ferrucci, J. S. Fok, D. Fomina, L. Fonacier, G. Fouda, I. Francescantonio, A. Fukunaga, C. A. Galvan Calle, E. Garcia, K. Gáspár, A. Gelincik, S. Geng, K. Godse, M. Gonçalo, M. Gotua, C. Grattan, M. Grosber, G. Guidos Fogelbach, M. Guilarte, R. Guillod, E. Hamelmann, J. Hawkes, K. Hayama, R. Heuer, M. Hide, W. Hoetzenecker, N. Inomata, H.‐R. Kang, A. Kaplan, A. Kapp, M. Karam, A. Kasperska‐Zajac, C. H. Katelaris, A. Kessel, M. Khoshkhui, B. Kim, T. Kinaciyan, E. Kocatürk, M. Kolacinska‐Flont, P. Kolkhir, G. N. Konstantinou, M. Kosnik, D. Krasowska, K. Kulthanan, M. S. Kumaran, I. Kuprys‐Lipinska, M. Labrador, J. I. Larco, D. Larenas‐Linnemann, E. Latysheva, E. Lazaridou, P. H. Li, H. Lima, U. Lippert, M. Magerl, M. Makris, J. Alves Marcelino, A. V. Marzano, I. Medina, R. Meshkova, D. Micallef, R. Mohammed Ali, C. G. Mortz, M. Munoz, H. N. G. Oude Elberink, A. Nakonechna, I. Nasr, A. Nast, E. Netchiporouk, E. Nettis, S. Nieto, I. Ogueta Canales, T.‐L. Okas, R. L. Orfali, E. Özkaya, C. Parisi, A. Pennitz, R. Pawankar, M. P. Pereira, J. Peter, E. Petkova, P. D. Pigatto, I. Podder, T. Popov, G. Porebski, P. Pyatilova, G. D. Ramon, H. A. Ratti Sisa, M. Recto, K. Ress, K. Ridge, M. Riedl, C. Ritchie, N. Rosario Filho, I. Rosmaninho, M. Rudenko, M. Rukhadze, K. Rutkowski, V. Sabato, U. M. Sahiner, S. Saini, F. Saleh Al Sabbagh, A. Salman, F. Salvo, J. Sanchez, A. Santucci, S. Schliemann, P. Schmid‐Grendelmeier, B. E. Sekerel, F. Serpa, F. Sheikh, J. Sheikh, H. Shendi, F. Siebenhaar, M. Sonomjamts, A. Soria, B. Sousa Pinto, M. Staevska, P. Staubach, M. Stephan, K. Stevanovic, L. Stingeni, M. Stobiecki, Ö. Su Küçük, G. Sussman, A. Szegedi, S. Takahagi, A. Tanaka, N. Teovska Mitrevska, S. F. Thomsen, E. Toubi, F. Tsatsou, M. Turk, Z. Vadasz, A. Valerieva, S. Valle, M. v. Doorn, B. Veleiro Perez, C. E. Vera Ayala, C. Vestergaard, R. J. Vieira, C. W. Maruta, B. Wedi, R. N. Werner, E. W. Y. Yap, P. Xepapadaki, Y. Xiang, Y.‐M. Ye, P. Yong, G. Yosipovitch, A. Z. J. Zalewska‐Janowska, C. Zeyen, Z. Zhao, M. Metz, A. M. Giménez‐Arnau +221 morewiley +1 more sourceTargeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice
Allergy, EarlyView.ABSTRACT
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...Harold Wilson‐Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E. Wechsler, Salman Siddiqui +7 morewiley +1 more source